Keywords: Novartis, Rasival, Withdraws European marketing application, EMEA, Onbrez, Lung function. COPD

Novartis pulls European marketing authorization application for aliskiren and valsartan combo Rasival; presents new data on Onbrez Breezhaler

Article | 20 September 2010

Print This

The European Medicines Agency (EMEA) has been formally notified by Swiss drug major Novartis (NOVN. VX) of its decision to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in